• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • View Item
  •   LillOA Home
  • Liste des unités
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Patterns of response to crizotinib in ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article original
DOI :
10.2217/cns.15.30
PMID :
26498130
Permalink :
http://hdl.handle.net/20.500.12210/16110
Title :
Patterns of response to crizotinib in recurrent glioblastoma according to alk and met molecular profile in two patients
Author(s) :
Le Rhun, Emilie [Auteur] refId
Chamberlain, Marc C. [Auteur]
Zairi, Fahed [Auteur]
Delmaire, Christine [Auteur] refId
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Idbaih, Ahmed [Auteur]
Renaud, Florence [Auteur] refId
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172


Maurage, Claude-Alain [Auteur] refId
Lille Neurosciences & Cognition (LilNCog) - U 1172

Gregoire, Valerie [Auteur]
Journal title :
CNS oncology
Abbreviated title :
CNS Oncol
Volume number :
4
Pages :
381-6
Publication date :
2015-01-01
ISSN :
2045-0915
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, ...
Show more >
Two patients with an unmethylated MGMT promoter and IDH1 (R132H) wild-type recurrent glioblastoma were treated with crizotinib. Prolonged stabilization of the disease (17 months) was achieved in the first case. Interestingly, anaplastic lymphoma kinase (ALK) expression and c-MET protein overexpression was observed. Conversely, no response to crizotinib was obtained in the second case with MET protein overexpression and c-MET amplification but no ALK expression or ALK gene amplification. These case studies suggest that novel targeted ALK inhibitors may provide relevant clinical benefit in selected cases in which driver mutations are demonstrable.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
INSERM
Inserm
Université de Lille
Collections :
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
  • Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Submission date :
2019-11-27T13:33:33Z
Université de Lille

Mentions légales
Université de Lille © 2017